NASDAQ:BPTH Bio-Path Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bio-Path Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.17 +0.05 (+1.21%) (As of 07/6/2022 02:17 PM ET) Add Compare Share Today's Range$4.17▼$4.1750-Day Range$2.84▼$4.1252-Week Range$2.68▼$8.62Volume10 shsAverage Volume44,638 shsMarket Capitalization$29.86 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bio-Path MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.4% Upside$9.00 Price TargetShort InterestBearish5.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.89) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.54 out of 5 starsMedical Sector970th out of 1,426 stocksPharmaceutical Preparations Industry478th out of 682 stocks 3.5 Analyst's Opinion Consensus RatingBio-Path has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Bio-Path has a forecasted upside of 118.4% from its current price of $4.12.Amount of Analyst CoverageBio-Path has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.17% of the float of Bio-Path has been sold short.Short Interest Ratio / Days to CoverBio-Path has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Path has recently increased by 8.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBio-Path does not currently pay a dividend.Dividend GrowthBio-Path does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPTH. Previous Next 1.8 News and Social Media Coverage News SentimentBio-Path has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Bio-Path this week, compared to 4 articles on an average week.Search Interest2 people have searched for BPTH on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Path insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.28% of the stock of Bio-Path is held by insiders.Percentage Held by InstitutionsOnly 6.29% of the stock of Bio-Path is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bio-Path are expected to grow in the coming year, from ($1.89) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Path is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Path is -2.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBio-Path has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BPTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Path and its competitors with MarketBeat's FREE daily newsletter. Email Address About Bio-Path (NASDAQ:BPTH) StockBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.Read More BPTH Stock News HeadlinesJuly 5, 2022 | finance.yahoo.comEurofins Discovery Announces Acquisition of DiscoveryBioMed - Yahoo FinanceJuly 1, 2022 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.comJune 29, 2022 | reuters.comLawyer for key Jan. 6 witness worked across administrations at Justice Department - Reuters.comJune 27, 2022 | businesswire.comNuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors - Business WireJune 23, 2022 | seekingalpha.comIVERIC bio Stock: A First Take (NASDAQ:ISEE) - Seeking AlphaJune 23, 2022 | americanbankingnews.comBio-Path (NASDAQ:BPTH) Now Covered by StockNews.comJune 22, 2022 | seekingalpha.combluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) - Seeking AlphaJune 21, 2022 | bloomberg.comAt BIO, the Biotech Industry's Major Conference, the Mood Was Sour - BloombergJune 20, 2022 | businesswire.comGlobal Antisense & RNAi Therapeutics Market Research Report 2022: Technology, Route, Indication Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F - ResearchAndMarkets.com - Business WireJune 17, 2022 | americanbankingnews.comShort Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Declines By 17.8%June 16, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)June 15, 2022 | forbes.comBiotechnology's Path To Web3 - ForbesJune 14, 2022 | finance.yahoo.comGood News from Taiwan Participants in BIO 2022 - Pharmasaga and PrecisemAb Make It to the Start-Up Stadium Finalists Defeating Hundred Teams - Yahoo FinanceJune 8, 2022 | seekingalpha.comIVERIC Bio stock rises after BofA, Guggenheim initiate with buy ratings - Seeking AlphaJune 6, 2022 | businesswire.comAdicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting - Business WireJune 2, 2022 | nytimes.comDoctors Transplant 3-D Printed Ear Made of Human Cells - The New York TimesJune 1, 2022 | ft.comTether's path to the spotlight - Financial TimesMay 31, 2022 | finance.yahoo.comWILLOW BIOSCIENCES EXPANDS ITS PORTFOLIO WITH A NEW PARTNERED PHARMACEUTICAL PROJECT - Yahoo FinanceMay 17, 2022 | apnews.comBio-Path: Q1 Earnings Snapshot - The Associated Press - en EspañolMay 17, 2022 | benzinga.comThe Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Lice - BenzingaMay 17, 2022 | benzinga.comBio-Path Holdings: Q1 Earnings Insights - Benzinga - BenzingaMay 17, 2022 | globenewswire.comBio-Path Holdings Reports First Quarter 2022 Financial Results - GlobeNewswireMay 17, 2022 | finance.yahoo.comBio-Path Holdings Reports First Quarter 2022 Financial ResultsMay 16, 2022 | benzinga.comA Preview Of Bio-Path Holdings's Earnings - Benzinga - BenzingaMay 16, 2022 | finance.yahoo.comWe Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth CarefullySee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPTH CUSIPN/A CIK1133818 Webwww.biopathholdings.com Phone(832) 742-1357FaxN/AEmployees10Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/06/2022Next Earnings (Estimated)8/12/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+115.8%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,440,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.49% Return on Assets-40.38% Debt Debt-to-Equity RatioN/A Current Ratio15.06 Quick Ratio15.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.56 per share Price / Book1.17Miscellaneous Outstanding Shares7,160,000Free Float6,997,000Market Cap$29.86 million OptionableNot Optionable Beta1.62 Bio-Path Frequently Asked Questions Should I buy or sell Bio-Path stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock. View analyst ratings for Bio-Path or view top-rated stocks. What is Bio-Path's stock price forecast for 2022? 1 equities research analysts have issued 1 year price targets for Bio-Path's stock. Their BPTH stock forecasts range from $9.00 to $9.00. On average, they predict Bio-Path's stock price to reach $9.00 in the next year. This suggests a possible upside of 115.8% from the stock's current price. View analysts' price targets for Bio-Path or view top-rated stocks among Wall Street analysts. How has Bio-Path's stock performed in 2022? Bio-Path's stock was trading at $3.77 at the beginning of 2022. Since then, BPTH shares have increased by 10.6% and is now trading at $4.17. View the best growth stocks for 2022 here. When is Bio-Path's next earnings date? Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Bio-Path. How were Bio-Path's earnings last quarter? Bio-Path Holdings, Inc. (NASDAQ:BPTH) posted its earnings results on Monday, May, 16th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.01. During the same quarter last year, the firm posted ($0.43) earnings per share. View Bio-Path's earnings history. When did Bio-Path's stock split? How did Bio-Path's stock split work? Bio-Path's stock reverse split on the morning of Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split. Who are Bio-Path's key executives? Bio-Path's management team includes the following people: Mr. Peter H. Nielsen MBA, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 73, Pay $680.18k)Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 66, Pay $68.47k)Mr. Anthony Price, Sr. VP of Fin., Accounting & Admin.Dr. Ana Tari Ashizawa Ph.D., MBA, Sr. VP of Research, Devel. & Clinical DesignDr. Alan MacKenzie Ph.D., ConsultantDr. Thomas A. Walker Ph.D., ConsultantDr. Jeffery Lancet M.D., ConsultantMs. Victoria Lake Rac, Regulatory Consultant Who are some of Bio-Path's key competitors? Some companies that are related to Bio-Path include Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Akouos (AKUS), Werewolf Therapeutics (HOWL), Paratek Pharmaceuticals (PRTK), Gelesis (GLS), Nabriva Therapeutics (NBRV), PDS Biotechnology (PDSB), Homology Medicines (FIXX), ESSA Pharma (EPIX), Greenwich LifeSciences (GLSI), Annovis Bio (ANVS), Enochian Biosciences (ENOB), Anebulo Pharmaceuticals (ANEB) and Xeris Biopharma (XERS). View all of BPTH's competitors. What other stocks do shareholders of Bio-Path own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC). What is Bio-Path's stock symbol? Bio-Path trades on the NASDAQ under the ticker symbol "BPTH." How do I buy shares of Bio-Path? Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bio-Path's stock price today? One share of BPTH stock can currently be purchased for approximately $4.17. How much money does Bio-Path make? Bio-Path (NASDAQ:BPTH) has a market capitalization of $29.86 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. How many employees does Bio-Path have? Bio-Path employs 10 workers across the globe. How can I contact Bio-Path? Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The official website for Bio-Path is www.biopathholdings.com. The company can be reached via phone at (832) 742-1357 or via email at will@sternir.com. This page (NASDAQ:BPTH) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
